Loading...
Loading...
Dyax Corp.
DYAX today announced that the U.S. Food and Drug
Administration (FDA) has granted orphan drug designation to its drug
candidate DX-2930, its fully human monoclonal antibody inhibitor of
plasma kallikrein, for use in the treatment of hereditary angioedema
(HAE).
Dyax is developing DX-2930 to be a long-acting, prophylactic agent that
prevents HAE attacks. Development plans include a dosage formulation
that will permit infrequent self-administration by small volume,
subcutaneous injection. DX-2930 is currently being studied in a
placebo-controlled, dose-escalation Phase 1 trial in normal individuals.
Results from this study are expected in the first quarter of 2014.
“Through our experience in the development and commercialization of
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in